ID   TP53B_HUMAN             Reviewed;        1972 AA.
AC   Q12888; F8VY86; Q2M1Z7; Q4LE46; Q5FWZ3; Q7Z3U4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   28-JUN-2023, entry version 232.
DE   RecName: Full=TP53-binding protein 1 {ECO:0000305};
DE            Short=53BP1 {ECO:0000303|PubMed:9748285};
DE            Short=p53-binding protein 1 {ECO:0000303|PubMed:9748285};
DE            Short=p53BP1;
GN   Name=TP53BP1 {ECO:0000312|HGNC:HGNC:11999};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9748285; DOI=10.1074/jbc.273.40.26061;
RA   Iwabuchi K., Li B., Massa H.F., Trask B.J., Date T., Fields S.;
RT   "Stimulation of p53-mediated transcriptional activation by the p53-binding
RT   proteins, 53BP1 and 53BP2.";
RL   J. Biol. Chem. 273:26061-26068(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Myeloid leukemia cell;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS GLU-353;
RP   SER-412 AND GLN-1136.
RC   TISSUE=Cervix;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-353; SER-412; VAL-648;
RP   ARG-699; GLY-1014; ALA-1026; GLN-1136; GLY-1170 AND VAL-1174.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 946-1972.
RX   PubMed=8016121; DOI=10.1073/pnas.91.13.6098;
RA   Iwabuchi K., Bartel P.L., Li B., Marraccino R., Fields S.;
RT   "Two cellular proteins that bind to wild-type but not mutant p53.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6098-6102(1994).
RN   [8]
RP   PHOSPHORYLATION.
RX   PubMed=11042216; DOI=10.1074/jbc.m007665200;
RA   Xia Z., Morales J.C., Dunphy W.G., Carpenter P.B.;
RT   "Negative cell cycle regulation and DNA-damage inducible phosphorylation of
RT   the BRCT protein 53BP1.";
RL   J. Biol. Chem. 276:2708-2718(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=11331310; DOI=10.1083/jcb.153.3.613;
RA   Rappold I., Iwabuchi K., Date T., Chen J.;
RT   "Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-
RT   signaling pathways.";
RL   J. Cell Biol. 153:613-620(2001).
RN   [10]
RP   FUNCTION IN DNA DAMAGE CHECKPOINT, AND INTERACTION WITH CHEK2.
RX   PubMed=12364621; DOI=10.1126/science.1076182;
RA   Wang B., Matsuoka S., Carpenter P.B., Elledge S.J.;
RT   "53BP1, a mediator of the DNA damage checkpoint.";
RL   Science 298:1435-1438(2002).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12824158; DOI=10.1074/jbc.m304066200;
RA   Iwabuchi K., Basu B.P., Kysela B., Kurihara T., Shibata M., Guan D.,
RA   Cao Y., Hamada T., Imamura K., Jeggo P.A., Date T., Doherty A.J.;
RT   "Potential role for 53BP1 in DNA end-joining repair through direct
RT   interaction with DNA.";
RL   J. Biol. Chem. 278:36487-36495(2003).
RN   [12]
RP   INTERACTION WITH H2AX.
RX   PubMed=12607005; DOI=10.1038/nature01446;
RA   Stewart G.S., Wang B., Bignell C.R., Taylor A.M.R., Elledge S.J.;
RT   "MDC1 is a mediator of the mammalian DNA damage checkpoint.";
RL   Nature 421:961-966(2003).
RN   [13]
RP   CHROMOSOMAL TRANSLOCATION WITH PDGFRB.
RX   PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005;
RA   Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J.,
RA   Chase A.J., Cross N.C.;
RT   "p53-Binding protein 1 is fused to the platelet-derived growth factor
RT   receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-
RT   responsive eosinophilic myeloproliferative disorder.";
RL   Cancer Res. 64:7216-7219(2004).
RN   [14]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15574327; DOI=10.1016/j.molcel.2004.10.029;
RA   Riballo E., Kuehne M., Rief N., Doherty A., Smith G.C.M., Recio M.-J.,
RA   Reis C., Dahm K., Fricke A., Krempler A., Parker A.R., Jackson S.P.,
RA   Gennery A., Jeggo P.A., Loebrich M.;
RT   "A pathway of double-strand break rejoining dependent upon ATM, Artemis,
RT   and proteins locating to gamma-H2AX foci.";
RL   Mol. Cell 16:715-724(2004).
RN   [15]
RP   METHYLATION, MUTAGENESIS OF ARG-1396; ARG-1398; ARG-1400; ARG-1401 AND
RP   ARG-1403, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=16294045; DOI=10.4161/cc.4.12.2250;
RA   Boisvert F.-M., Rhie A., Richard S., Doherty A.J.;
RT   "The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary
RT   for 53BP1 DNA binding activity.";
RL   Cell Cycle 4:1834-1841(2005).
RN   [16]
RP   METHYLATION, MUTAGENESIS OF ARG-1396; ARG-1398; ARG-1400; ARG-1401 AND
RP   ARG-1403, SUBUNIT, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=16294047; DOI=10.4161/cc.4.12.2282;
RA   Adams M.M., Wang B., Xia Z., Morales J.C., Lu X., Donehower L.A.,
RA   Bochar D.A., Elledge S.J., Carpenter P.B.;
RT   "53BP1 oligomerization is independent of its methylation by PRMT1.";
RL   Cell Cycle 4:1854-1861(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-294; SER-500;
RP   SER-635; SER-639; SER-640; SER-1094; SER-1219; SER-1362 AND SER-1678, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-834 AND SER-1426, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   PHOSPHORYLATION AT SER-166; SER-176; SER-178; SER-294; THR-302; SER-380;
RP   SER-452; SER-523; SER-552; SER-831; SER-1028; SER-1086; SER-1114 AND
RP   SER-1219, AND MUTAGENESIS OF 176-SER--SER-178.
RX   PubMed=17553757; DOI=10.1016/j.dnarep.2007.04.011;
RA   Jowsey P., Morrice N.A., Hastie C.J., McLauchlan H., Toth R., Rouse J.;
RT   "Characterisation of the sites of DNA damage-induced 53BP1 phosphorylation
RT   catalysed by ATM and ATR.";
RL   DNA Repair 6:1536-1544(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; THR-302; SER-523;
RP   THR-543; THR-548; SER-552; SER-831; THR-855; THR-1214; SER-1216 AND
RP   SER-1219, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-265; SER-395;
RP   SER-398; SER-500; SER-523; SER-525; SER-552; SER-809; SER-831; SER-1028;
RP   SER-1094; SER-1216; SER-1219; SER-1368; THR-1372; SER-1426; SER-1430;
RP   SER-1462; THR-1609; SER-1701 AND SER-1759, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   PHOSPHORYLATION AT SER-25 AND SER-1778, DEPHOSPHORYLATION AT SER-25 AND
RP   SER-1778 BY PPP5C, AND SUBCELLULAR LOCATION.
RX   PubMed=19176521; DOI=10.1074/jbc.m809272200;
RA   Kang Y., Lee J.H., Hoan N.N., Sohn H.M., Chang I.Y., You H.J.;
RT   "Protein phosphatase 5 regulates the function of 53BP1 after
RT   neocarzinostatin-induced DNA damage.";
RL   J. Biol. Chem. 284:9845-9853(2009).
RN   [25]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS BZLF1 PROTEIN (MICROBIAL INFECTION).
RX   PubMed=19656881; DOI=10.1128/jvi.00512-09;
RA   Bailey S.G., Verrall E., Schelcher C., Rhie A., Doherty A.J.,
RA   Sinclair A.J.;
RT   "Functional interaction between Epstein-Barr virus replication protein Zta
RT   and host DNA damage response protein 53BP1.";
RL   J. Virol. 83:11116-11122(2009).
RN   [26]
RP   INTERACTION WITH MSL1.
RX   PubMed=19650074; DOI=10.1002/jcp.21889;
RA   Gironella M., Malicet C., Cano C., Sandi M.J., Hamidi T., Tauil R.M.,
RA   Baston M., Valaco P., Moreno S., Lopez F., Neira J.L., Dagorn J.C.,
RA   Iovanna J.L.;
RT   "p8/nupr1 regulates DNA-repair activity after double-strand gamma
RT   irradiation-induced DNA damage.";
RL   J. Cell. Physiol. 221:594-602(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294; SER-366; SER-380;
RP   SER-500; SER-523; SER-525; THR-543; SER-552; SER-834; SER-1028; SER-1114;
RP   SER-1426; SER-1430; SER-1460; SER-1462 AND SER-1474, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [28]
RP   INTERACTION WITH PWWP3A.
RX   PubMed=20347427; DOI=10.1016/j.molcel.2009.12.040;
RA   Huen M.S., Huang J., Leung J.W., Sy S.M., Leung K.M., Ching Y.P.,
RA   Tsao S.W., Chen J.;
RT   "Regulation of chromatin architecture by the PWWP domain-containing DNA
RT   damage-responsive factor EXPAND1/MUM1.";
RL   Mol. Cell 37:854-864(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-294; SER-500;
RP   SER-525; SER-552; SER-566; SER-580; SER-639; SER-640; SER-809; THR-922;
RP   SER-970; SER-975; SER-1028; SER-1068; SER-1114; SER-1362; SER-1426;
RP   SER-1430; THR-1609; SER-1618 AND SER-1678, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION IN DNA DAMAGE RESPONSE, PHOSPHORYLATION AT SER-1778, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005;
RA   Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y.,
RA   You H.J.;
RT   "Protein phosphatase 5 is necessary for ATR-mediated DNA repair.";
RL   Biochem. Biophys. Res. Commun. 404:476-481(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-294; SER-500;
RP   SER-525; SER-552; SER-809; SER-1028; SER-1101; SER-1114; SER-1362;
RP   SER-1430; SER-1618 AND SER-1678, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   FUNCTION.
RX   PubMed=22553214; DOI=10.1242/jcs.105353;
RA   Chapman J.R., Sossick A.J., Boulton S.J., Jackson S.P.;
RT   "BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies
RT   temporal control of DNA repair.";
RL   J. Cell Sci. 125:3529-3534(2012).
RN   [34]
RP   FUNCTION, PHOSPHORYLATION, INTERACTION WITH RIF1 AND PAXIP1, AND
RP   MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29; SER-105; SER-166; SER-176 AND
RP   SER-178.
RX   PubMed=23727112; DOI=10.1016/j.cell.2013.05.023;
RA   Callen E., Di Virgilio M., Kruhlak M.J., Nieto-Soler M., Wong N.,
RA   Chen H.T., Faryabi R.B., Polato F., Santos M., Starnes L.M., Wesemann D.R.,
RA   Lee J.E., Tubbs A., Sleckman B.P., Daniel J.A., Ge K., Alt F.W.,
RA   Fernandez-Capetillo O., Nussenzweig M.C., Nussenzweig A.;
RT   "53BP1 mediates productive and mutagenic DNA repair through distinct
RT   phosphoprotein interactions.";
RL   Cell 153:1266-1280(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63; SER-124; SER-222;
RP   SER-265; SER-294; SER-366; SER-380; SER-398; SER-500; SER-507; SER-518;
RP   SER-523; SER-525; SER-552; SER-580; SER-771; SER-809; SER-834; THR-922;
RP   SER-1028; THR-1056; SER-1068; SER-1094; SER-1114; SER-1148; SER-1216;
RP   SER-1219; SER-1317; SER-1342; SER-1362; SER-1426; SER-1430; SER-1462;
RP   THR-1609; SER-1618; SER-1635; THR-1638; THR-1648; SER-1656; SER-1673;
RP   SER-1678 AND SER-1701, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RIF1, PHOSPHORYLATION, AND
RP   MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29; SER-105; SER-166; SER-176;
RP   SER-178; THR-302; SER-437; SER-452; SER-523; THR-543; SER-580; SER-625;
RP   SER-674; THR-696; SER-698; SER-784; SER-831; THR-855; SER-892; SER-1068;
RP   SER-1086; SER-1104; SER-1148; THR-1171 AND SER-1219.
RX   PubMed=23333306; DOI=10.1016/j.molcel.2013.01.001;
RA   Escribano-Diaz C., Orthwein A., Fradet-Turcotte A., Xing M., Young J.T.,
RA   Tkac J., Cook M.A., Rosebrock A.P., Munro M., Canny M.D., Xu D.,
RA   Durocher D.;
RT   "A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and
RT   BRCA1-CtIP controls DNA repair pathway choice.";
RL   Mol. Cell 49:872-883(2013).
RN   [37]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF
RP   ASP-1521; LYS-1613; ASP-1616; ILE-1617; LEU-1619; ASN-1621; LEU-1622;
RP   GLU-1624 AND ARG-1627.
RX   PubMed=23760478; DOI=10.1038/nature12318;
RA   Fradet-Turcotte A., Canny M.D., Escribano-Diaz C., Orthwein A., Leung C.C.,
RA   Huang H., Landry M.C., Kitevski-LeBlanc J., Noordermeer S.M., Sicheri F.,
RA   Durocher D.;
RT   "53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.";
RL   Nature 499:50-54(2013).
RN   [38]
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29;
RP   SER-105; SER-166; SER-176; SER-178; THR-302; SER-437; SER-452; SER-523;
RP   THR-543; SER-580; SER-625; SER-674; THR-696; SER-698; SER-784; SER-831;
RP   THR-855; SER-892; SER-1068; SER-1086; SER-1104; SER-1148; THR-1171;
RP   SER-1219; 1398-ARG--ARG-1401 AND ASP-1521.
RX   PubMed=23345425; DOI=10.1073/pnas.1222617110;
RA   Lottersberger F., Bothmer A., Robbiani D.F., Nussenzweig M.C., de Lange T.;
RT   "Role of 53BP1 oligomerization in regulating double-strand break repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:2146-2151(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294; SER-500; SER-552;
RP   SER-630; SER-692; SER-727; SER-1114; SER-1216 AND SER-1362, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-1609 AND SER-1618, DOMAIN, AND
RP   MUTAGENESIS OF THR-1609 AND SER-1618.
RX   PubMed=24703952; DOI=10.1016/j.molcel.2014.03.020;
RA   Lee D.H., Acharya S.S., Kwon M., Drane P., Guan Y., Adelmant G., Kalev P.,
RA   Shah J., Pellman D., Marto J.A., Chowdhury D.;
RT   "Dephosphorylation enables the recruitment of 53BP1 to double-strand DNA
RT   breaks.";
RL   Mol. Cell 54:512-525(2014).
RN   [41]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-930 AND LYS-1563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [42]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-217; LYS-868; LYS-1434 AND
RP   LYS-1563, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [43]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-930, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [44]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1563, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [45]
RP   FUNCTION.
RX   PubMed=27153538; DOI=10.1016/j.molcel.2016.03.031;
RA   Jacquet K., Fradet-Turcotte A., Avvakumov N., Lambert J.P., Roques C.,
RA   Pandita R.K., Paquet E., Herst P., Gingras A.C., Pandita T.K., Legube G.,
RA   Doyon Y., Durocher D., Cote J.;
RT   "The TIP60 complex regulates bivalent chromatin recognition by 53BP1
RT   through direct H4K20me binding and H2AK15 acetylation.";
RL   Mol. Cell 62:409-421(2016).
RN   [46]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-217; LYS-868; LYS-930; LYS-984;
RP   LYS-1365; LYS-1434 AND LYS-1563, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [47]
RP   FUNCTION, INTERACTION WITH NUDT16L1 AND RIF1, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF TRP-1495; ASP-1521; THR-1609 AND
RP   SER-1618.
RX   PubMed=28241136; DOI=10.1038/nature21358;
RA   Drane P., Brault M.E., Cui G., Meghani K., Chaubey S., Detappe A.,
RA   Parnandi N., He Y., Zheng X.F., Botuyan M.V., Kalousi A., Yewdell W.T.,
RA   Muench C., Harper J.W., Chaudhuri J., Soutoglou E., Mer G., Chowdhury D.;
RT   "TIRR regulates 53BP1 by masking its histone methyl-lysine binding
RT   function.";
RL   Nature 543:211-216(2017).
RN   [48]
RP   INTERACTION WITH SHLD2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29789392; DOI=10.15252/embj.201899543;
RA   Tomida J., Takata K.I., Bhetawal S., Person M.D., Chao H.P., Tang D.G.,
RA   Wood R.D.;
RT   "FAM35A associates with REV7 and modulates DNA damage responses of normal
RT   and BRCA1-defective cells.";
RL   EMBO J. 37:0-0(2018).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1722-1971 IN COMPLEX WITH TP53.
RX   PubMed=12110597; DOI=10.1093/emboj/cdf383;
RA   Derbyshire D.J., Basu B.P., Serpell L.C., Joo W.S., Date T., Iwabuchi K.,
RA   Doherty A.J.;
RT   "Crystal structure of human 53BP1 BRCT domains bound to p53 tumour
RT   suppressor.";
RL   EMBO J. 21:3863-3872(2002).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1714-1972 IN COMPLEX WITH TP53.
RX   PubMed=11877378; DOI=10.1101/gad.959202;
RA   Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M.,
RA   Pavletich N.P.;
RT   "Structure of the 53BP1 BRCT region bound to p53 and its comparison to the
RT   Brca1 BRCT structure.";
RL   Genes Dev. 16:583-593(2002).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1485-1602, INTERACTION WITH
RP   METHYLATED HISTONE H3 AND HISTONE H4, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF TRP-1495; TYR-1502 AND ASP-1521.
RX   PubMed=15525939; DOI=10.1038/nature03114;
RA   Huyen Y., Zgheib O., Ditullio R.A. Jr., Gorgoulis V.G., Zacharatos P.,
RA   Petty T.J., Sheston E.A., Mellert H.S., Stavridi E.S., Halazonetis T.D.;
RT   "Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand
RT   breaks.";
RL   Nature 432:406-411(2004).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1484-1603 IN COMPLEX WITH HISTONE
RP   H4, SUBUNIT, FUNCTION, MUTAGENESIS OF TRP-1495; TYR-1500; TYR-1502;
RP   ASP-1521 AND TYR-1523, AND SUBCELLULAR LOCATION.
RX   PubMed=17190600; DOI=10.1016/j.cell.2006.10.043;
RA   Botuyan M.V., Lee J., Ward I.M., Kim J.-E., Thompson J.R., Chen J., Mer G.;
RT   "Structural basis for the methylation state-specific recognition of histone
RT   H4-K20 by 53BP1 and Crb2 in DNA repair.";
RL   Cell 127:1361-1373(2006).
CC   -!- FUNCTION: Double-strand break (DSB) repair protein involved in response
CC       to DNA damage, telomere dynamics and class-switch recombination (CSR)
CC       during antibody genesis (PubMed:12364621, PubMed:22553214,
CC       PubMed:23333306, PubMed:17190600, PubMed:21144835, PubMed:27153538,
CC       PubMed:28241136). Plays a key role in the repair of double-strand DNA
CC       breaks (DSBs) in response to DNA damage by promoting non-homologous end
CC       joining (NHEJ)-mediated repair of DSBs and specifically counteracting
CC       the function of the homologous recombination (HR) repair protein BRCA1
CC       (PubMed:22553214, PubMed:23727112, PubMed:23333306, PubMed:27153538).
CC       In response to DSBs, phosphorylation by ATM promotes interaction with
CC       RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to
CC       DSBs sites (PubMed:28241136). Recruited to DSBs sites by recognizing
CC       and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and
CC       histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that
CC       are present at DSBs sites (PubMed:23760478, PubMed:27153538,
CC       PubMed:28241136, PubMed:17190600). Required for immunoglobulin class-
CC       switch recombination (CSR) during antibody genesis, a process that
CC       involves the generation of DNA DSBs (PubMed:23345425). Participates in
CC       the repair and the orientation of the broken DNA ends during CSR (By
CC       similarity). In contrast, it is not required for classic NHEJ and V(D)J
CC       recombination (By similarity). Promotes NHEJ of dysfunctional telomeres
CC       via interaction with PAXIP1 (PubMed:23727112).
CC       {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538,
CC       ECO:0000269|PubMed:28241136}.
CC   -!- SUBUNIT: Homoligomer (PubMed:16294047, PubMed:23760478,
CC       PubMed:23345425). Interacts with p53/TP53 (via the central domain)
CC       (PubMed:12110597, PubMed:11877378). Interacts with DCLRE1C
CC       (PubMed:15574327). Interacts with histone H2AX and this requires
CC       phosphorylation of H2AX on 'Ser-139' (PubMed:12607005). Interacts with
CC       histone H4 that has been dimethylated at 'Lys-20' (H4K20me2)
CC       (PubMed:17190600). Has low affinity for histone H4 containing
CC       monomethylated 'Lys-20' (H4K20me1) (PubMed:17190600). Does not bind
CC       histone H4 containing unmethylated or trimethylated 'Lys-20' (H4K20me3)
CC       (PubMed:17190600). Has low affinity for histone H3 that has been
CC       dimethylated on 'Lys-79' (PubMed:15525939). Has very low affinity for
CC       histone H3 that has been monomethylated on 'Lys-79' (in vitro)
CC       (PubMed:15525939). Does not bind unmethylated histone H3
CC       (PubMed:15525939). Interacts with histone H2A monoubiquitinated at
CC       'Lys-15' (H2AK15Ub) (PubMed:23760478). Interacts with PWWP3A/EXPAND1
CC       (PubMed:20347427). Interacts with CHEK2; modulates CHEK2
CC       phosphorylation at 'Thr-68' in response to infrared (PubMed:12364621).
CC       Interacts with MSL1; this interaction may be required for MSL1 DNA
CC       repair activity, but not for histone acetyltransferase activity
CC       (PubMed:19650074). Interacts (when phosphorylated by ATM) with RIF1
CC       (PubMed:23727112, PubMed:23333306, PubMed:28241136). Interacts (via the
CC       Tudor-like domain) with NUDT16L1/TIRR; interaction masks the Tudor-like
CC       domain and prevents recruitment to chromatin (PubMed:28241136).
CC       Interacts with PAXIP1 (PubMed:23727112). Interacts with SHLD2
CC       (PubMed:29789392). {ECO:0000269|PubMed:11877378,
CC       ECO:0000269|PubMed:12110597, ECO:0000269|PubMed:12364621,
CC       ECO:0000269|PubMed:12607005, ECO:0000269|PubMed:15525939,
CC       ECO:0000269|PubMed:15574327, ECO:0000269|PubMed:16294047,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:19650074,
CC       ECO:0000269|PubMed:20347427, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:29789392}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via C-terminus) with Epstein-
CC       Barr virus lytic switch protein BZLF1 (via C-terminus); this
CC       interaction is involved in the activation of the viral lytic cycle.
CC       {ECO:0000269|PubMed:19656881}.
CC   -!- INTERACTION:
CC       Q12888; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-396540, EBI-11954519;
CC       Q12888; Q13315: ATM; NbExp=2; IntAct=EBI-396540, EBI-495465;
CC       Q12888; P13637: ATP1A3; NbExp=3; IntAct=EBI-396540, EBI-948169;
CC       Q12888; P46379-2: BAG6; NbExp=3; IntAct=EBI-396540, EBI-10988864;
CC       Q12888; P41182: BCL6; NbExp=3; IntAct=EBI-396540, EBI-765407;
CC       Q12888; P38398: BRCA1; NbExp=5; IntAct=EBI-396540, EBI-349905;
CC       Q12888; Q5SWW7: C10orf55; NbExp=3; IntAct=EBI-396540, EBI-12809220;
CC       Q12888; P55212: CASP6; NbExp=3; IntAct=EBI-396540, EBI-718729;
CC       Q12888; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-396540, EBI-744556;
CC       Q12888; Q02930-3: CREB5; NbExp=3; IntAct=EBI-396540, EBI-10192698;
CC       Q12888; G5E9A7: DMWD; NbExp=3; IntAct=EBI-396540, EBI-10976677;
CC       Q12888; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-396540, EBI-12593112;
CC       Q12888; O14645: DNALI1; NbExp=3; IntAct=EBI-396540, EBI-395638;
CC       Q12888; P50570-2: DNM2; NbExp=3; IntAct=EBI-396540, EBI-10968534;
CC       Q12888; P16104: H2AX; NbExp=6; IntAct=EBI-396540, EBI-494830;
CC       Q12888; P62807: H2BC8; NbExp=6; IntAct=EBI-396540, EBI-354552;
CC       Q12888; P68431: H3C12; NbExp=5; IntAct=EBI-396540, EBI-79722;
CC       Q12888; P62805: H4C9; NbExp=14; IntAct=EBI-396540, EBI-302023;
CC       Q12888; O14964: HGS; NbExp=3; IntAct=EBI-396540, EBI-740220;
CC       Q12888; P10809: HSPD1; NbExp=3; IntAct=EBI-396540, EBI-352528;
CC       Q12888; O14901: KLF11; NbExp=3; IntAct=EBI-396540, EBI-948266;
CC       Q12888; Q96G42: KLHDC7B; NbExp=3; IntAct=EBI-396540, EBI-9478422;
CC       Q12888; P13473-2: LAMP2; NbExp=3; IntAct=EBI-396540, EBI-21591415;
CC       Q12888; P50222: MEOX2; NbExp=3; IntAct=EBI-396540, EBI-748397;
CC       Q12888; Q14686: NCOA6; NbExp=3; IntAct=EBI-396540, EBI-78670;
CC       Q12888; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-396540, EBI-12813389;
CC       Q12888; Q6ZW49: PAXIP1; NbExp=4; IntAct=EBI-396540, EBI-743225;
CC       Q12888; P16284: PECAM1; NbExp=3; IntAct=EBI-396540, EBI-716404;
CC       Q12888; P78337: PITX1; NbExp=3; IntAct=EBI-396540, EBI-748265;
CC       Q12888; Q13393: PLD1; NbExp=3; IntAct=EBI-396540, EBI-2827556;
CC       Q12888; P53350: PLK1; NbExp=6; IntAct=EBI-396540, EBI-476768;
CC       Q12888; D3DTS7: PMP22; NbExp=3; IntAct=EBI-396540, EBI-25882629;
CC       Q12888; P78424: POU6F2; NbExp=3; IntAct=EBI-396540, EBI-12029004;
CC       Q12888; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-396540, EBI-5280197;
CC       Q12888; P62826: RAN; NbExp=3; IntAct=EBI-396540, EBI-286642;
CC       Q12888; Q86V20-2: SHLD2; NbExp=3; IntAct=EBI-396540, EBI-20592761;
CC       Q12888; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-396540, EBI-5235340;
CC       Q12888; O43711: TLX3; NbExp=3; IntAct=EBI-396540, EBI-3939165;
CC       Q12888; P04637: TP53; NbExp=6; IntAct=EBI-396540, EBI-366083;
CC       Q12888; Q5T6F2: UBAP2; NbExp=3; IntAct=EBI-396540, EBI-2514383;
CC       Q12888; P61086: UBE2K; NbExp=3; IntAct=EBI-396540, EBI-473850;
CC       Q12888; Q08AM6: VAC14; NbExp=6; IntAct=EBI-396540, EBI-2107455;
CC       Q12888; P23763-3: VAMP1; NbExp=3; IntAct=EBI-396540, EBI-12097582;
CC       Q12888; P08670: VIM; NbExp=3; IntAct=EBI-396540, EBI-353844;
CC       Q12888; Q99986: VRK1; NbExp=8; IntAct=EBI-396540, EBI-1769146;
CC       Q12888; P04275-2: VWF; NbExp=3; IntAct=EBI-396540, EBI-25896548;
CC       Q12888; O43257: ZNHIT1; NbExp=2; IntAct=EBI-396540, EBI-347522;
CC       Q12888; Q6NZQ4: Paxip1; Xeno; NbExp=5; IntAct=EBI-396540, EBI-1395317;
CC       Q12888-1; P62805: H4C9; NbExp=3; IntAct=EBI-8022649, EBI-302023;
CC       Q12888-1; Q14686: NCOA6; NbExp=3; IntAct=EBI-8022649, EBI-78670;
CC       Q12888-1; P63165: SUMO1; NbExp=2; IntAct=EBI-8022649, EBI-80140;
CC       Q12888-1; P04637: TP53; NbExp=17; IntAct=EBI-8022649, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11331310,
CC       ECO:0000269|PubMed:15525939, ECO:0000269|PubMed:16294045,
CC       ECO:0000269|PubMed:16294047, ECO:0000269|PubMed:17190600,
CC       ECO:0000269|PubMed:19176521, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:9748285}. Chromosome
CC       {ECO:0000269|PubMed:12824158, ECO:0000269|PubMed:15525939,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:24703952,
CC       ECO:0000269|PubMed:28241136}. Chromosome, centromere, kinetochore
CC       {ECO:0000250|UniProtKB:P70399}. Note=Localizes to the nucleus in
CC       absence of DNA damage (PubMed:28241136). Following DNA damage,
CC       recruited to sites of DNA damage, such as double stand breaks (DSBs):
CC       recognizes and binds histone H2A monoubiquitinated at 'Lys-15'
CC       (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two
CC       histone marks that are present at DSBs sites (PubMed:23333306,
CC       PubMed:23760478, PubMed:24703952, PubMed:28241136, PubMed:17190600).
CC       Associated with kinetochores during mitosis (By similarity).
CC       {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:17190600,
CC       ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23760478,
CC       ECO:0000269|PubMed:28241136}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q12888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12888-2; Sequence=VSP_018390;
CC       Name=3;
CC         IsoId=Q12888-3; Sequence=VSP_018390, VSP_055062;
CC   -!- DOMAIN: The Tudor-like region mediates binding to histone H4
CC       dimethylated at 'Lys-20' (H4K20me2) (PubMed:17190600). Interaction with
CC       NUDT16L1/TIRR masks the Tudor-like domain and prevents recruitment to
CC       chromatin (PubMed:28241136). {ECO:0000269|PubMed:17190600,
CC       ECO:0000269|PubMed:28241136}.
CC   -!- DOMAIN: The UDR (ubiquitin-dependent recruitment) motif specifically
CC       recognizes and binds histone H2A monoubiquitinated at 'Lys-15'
CC       (H2AK15ub) (PubMed:23760478, PubMed:24703952). Phosphorylation of the
CC       UDR blocks interaction with H2AK15ub (PubMed:24703952).
CC       {ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:24703952}.
CC   -!- PTM: Asymmetrically dimethylated on Arg residues by PRMT1. Methylation
CC       is required for DNA binding. {ECO:0000269|PubMed:16294045,
CC       ECO:0000269|PubMed:16294047}.
CC   -!- PTM: Phosphorylated at basal level in the absence of DNA damage
CC       (PubMed:11042216, PubMed:11331310). Phosphorylated by ATM in response
CC       to DNA damage: phosphorylation at different sites promotes interaction
CC       with different set of proteins: phosphorylation at the N-terminus by
CC       ATM (residues from 6-178) promotes interaction with PAXIP1 and non-
CC       homologous end joining (NHEJ) of dysfunctional telomeres
CC       (PubMed:23727112). Phosphorylation by ATM at residues that are located
CC       more C-terminus (residues 300-650) leads to promote interaction with
CC       RIF1 (PubMed:23727112, PubMed:23333306, PubMed:28241136). Interaction
CC       with RIF1 leads to disrupt interaction with NUDT16L1/TIRR
CC       (PubMed:28241136). Phosphorylation at Thr-1609 and Ser-1618 in the UDR
CC       motif blocks interaction with H2AK15ub (PubMed:24703952).
CC       Dephosphorylated by PPP4C (PubMed:24703952). Hyperphosphorylation
CC       during mitosis correlates with its exclusion from chromatin and DNA
CC       lesions. Hyperphosphorylated in an ATR-dependent manner in response to
CC       DNA damage induced by UV irradiation (PubMed:17553757,
CC       PubMed:21144835). Dephosphorylated by PPP5C (PubMed:19176521).
CC       {ECO:0000269|PubMed:11042216, ECO:0000269|PubMed:11331310,
CC       ECO:0000269|PubMed:17553757, ECO:0000269|PubMed:19176521,
CC       ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23727112, ECO:0000269|PubMed:24703952,
CC       ECO:0000269|PubMed:28241136}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TP53BP1 is found in a
CC       form of myeloproliferative disorder chronic with eosinophilia.
CC       Translocation t(5;15)(q33;q22) with PDGFRB creating a TP53BP1-PDGFRB
CC       fusion protein. {ECO:0000269|PubMed:15492236}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06107.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53bp1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF078776; AAC62018.1; -; mRNA.
DR   EMBL; AB210025; BAE06107.1; ALT_INIT; mRNA.
DR   EMBL; BX537418; CAD97660.1; -; mRNA.
DR   EMBL; AY904026; AAW69392.1; -; Genomic_DNA.
DR   EMBL; AC018924; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC112161; AAI12162.1; -; mRNA.
DR   EMBL; U09477; AAA21596.1; -; mRNA.
DR   CCDS; CCDS10096.1; -. [Q12888-1]
DR   CCDS; CCDS45250.1; -. [Q12888-2]
DR   CCDS; CCDS45251.1; -. [Q12888-3]
DR   PIR; I38604; I38604.
DR   RefSeq; NP_001135451.1; NM_001141979.1. [Q12888-3]
DR   RefSeq; NP_001135452.1; NM_001141980.1. [Q12888-2]
DR   RefSeq; NP_005648.1; NM_005657.2. [Q12888-1]
DR   PDB; 1GZH; X-ray; 2.60 A; B/D=1724-1972.
DR   PDB; 1KZY; X-ray; 2.50 A; C/D=1714-1972.
DR   PDB; 1XNI; X-ray; 2.80 A; A/B/C/D/E/F/G/H/I/J=1485-1602.
DR   PDB; 2G3R; X-ray; 1.25 A; A=1484-1603.
DR   PDB; 2IG0; X-ray; 1.70 A; A=1484-1603.
DR   PDB; 2LVM; NMR; -; A=1484-1603.
DR   PDB; 2MWO; NMR; -; A=1484-1603.
DR   PDB; 2MWP; NMR; -; A=1484-1603.
DR   PDB; 3LGF; X-ray; 1.50 A; A=1484-1603.
DR   PDB; 3LGL; X-ray; 1.60 A; A=1484-1603.
DR   PDB; 3LH0; X-ray; 1.90 A; A=1484-1603.
DR   PDB; 4CRI; X-ray; 2.35 A; A/B=1459-1634.
DR   PDB; 4RG2; X-ray; 1.50 A; A/B=1483-1606.
DR   PDB; 4X34; X-ray; 1.80 A; A/B=1484-1603.
DR   PDB; 5ECG; X-ray; 3.00 A; C/D=1713-1972.
DR   PDB; 5J26; X-ray; 2.50 A; A=1487-1603.
DR   PDB; 5KGF; EM; 4.54 A; K/L=1611-1631.
DR   PDB; 5Z78; X-ray; 1.76 A; C=1484-1603.
DR   PDB; 5ZCJ; X-ray; 2.00 A; C=1459-1634.
DR   PDB; 6CO1; X-ray; 2.18 A; E/F=1484-1603.
DR   PDB; 6CO2; X-ray; 2.49 A; C/D=1484-1603.
DR   PDB; 6IU7; X-ray; 1.90 A; B=1665-1686.
DR   PDB; 6IUA; X-ray; 1.70 A; B=1665-1686.
DR   PDB; 6MXX; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J=1484-1603.
DR   PDB; 6MXY; X-ray; 1.62 A; A/B=1484-1603.
DR   PDB; 6MXZ; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J=1484-1603.
DR   PDB; 6MY0; X-ray; 2.20 A; A/B=1484-1603.
DR   PDB; 6RML; X-ray; 2.81 A; C=663-677.
DR   PDB; 6RMM; X-ray; 3.53 A; P/R=359-373.
DR   PDB; 6UPT; X-ray; 1.96 A; A/B=1483-1606.
DR   PDB; 6VA5; X-ray; 1.28 A; A=1483-1606.
DR   PDB; 6VIP; X-ray; 1.36 A; A/B=1483-1606.
DR   PDB; 7LIN; X-ray; 1.44 A; B=1636-1650.
DR   PDB; 7LIO; X-ray; 3.01 A; C/D=1636-1650.
DR   PDB; 7YQK; EM; 3.38 A; K=1613-1630, N=1485-1602.
DR   PDB; 8EOM; X-ray; 1.70 A; A/B=1483-1606.
DR   PDB; 8F0W; X-ray; 1.52 A; A/B=1483-1606.
DR   PDB; 8HKW; X-ray; 1.90 A; C/D=1665-1686.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1XNI; -.
DR   PDBsum; 2G3R; -.
DR   PDBsum; 2IG0; -.
DR   PDBsum; 2LVM; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 3LGF; -.
DR   PDBsum; 3LGL; -.
DR   PDBsum; 3LH0; -.
DR   PDBsum; 4CRI; -.
DR   PDBsum; 4RG2; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5J26; -.
DR   PDBsum; 5KGF; -.
DR   PDBsum; 5Z78; -.
DR   PDBsum; 5ZCJ; -.
DR   PDBsum; 6CO1; -.
DR   PDBsum; 6CO2; -.
DR   PDBsum; 6IU7; -.
DR   PDBsum; 6IUA; -.
DR   PDBsum; 6MXX; -.
DR   PDBsum; 6MXY; -.
DR   PDBsum; 6MXZ; -.
DR   PDBsum; 6MY0; -.
DR   PDBsum; 6RML; -.
DR   PDBsum; 6RMM; -.
DR   PDBsum; 6UPT; -.
DR   PDBsum; 6VA5; -.
DR   PDBsum; 6VIP; -.
DR   PDBsum; 7LIN; -.
DR   PDBsum; 7LIO; -.
DR   PDBsum; 7YQK; -.
DR   PDBsum; 8EOM; -.
DR   PDBsum; 8F0W; -.
DR   PDBsum; 8HKW; -.
DR   AlphaFoldDB; Q12888; -.
DR   BMRB; Q12888; -.
DR   SMR; Q12888; -.
DR   BioGRID; 113011; 516.
DR   CORUM; Q12888; -.
DR   DIP; DIP-5978N; -.
DR   IntAct; Q12888; 367.
DR   MINT; Q12888; -.
DR   STRING; 9606.ENSP00000371475; -.
DR   BindingDB; Q12888; -.
DR   ChEMBL; CHEMBL2424509; -.
DR   GlyCosmos; Q12888; 3 sites, 1 glycan.
DR   GlyGen; Q12888; 10 sites, 1 O-linked glycan (10 sites).
DR   iPTMnet; Q12888; -.
DR   MetOSite; Q12888; -.
DR   PhosphoSitePlus; Q12888; -.
DR   SwissPalm; Q12888; -.
DR   BioMuta; TP53BP1; -.
DR   DMDM; 8928568; -.
DR   CPTAC; CPTAC-1014; -.
DR   CPTAC; CPTAC-1015; -.
DR   CPTAC; CPTAC-1334; -.
DR   CPTAC; CPTAC-2608; -.
DR   CPTAC; CPTAC-2609; -.
DR   CPTAC; CPTAC-5914; -.
DR   CPTAC; CPTAC-5915; -.
DR   CPTAC; CPTAC-5916; -.
DR   CPTAC; CPTAC-5917; -.
DR   EPD; Q12888; -.
DR   jPOST; Q12888; -.
DR   MassIVE; Q12888; -.
DR   MaxQB; Q12888; -.
DR   PaxDb; Q12888; -.
DR   PeptideAtlas; Q12888; -.
DR   ProteomicsDB; 29194; -.
DR   ProteomicsDB; 59003; -. [Q12888-1]
DR   ProteomicsDB; 59004; -. [Q12888-2]
DR   ABCD; Q12888; 6 sequenced antibodies.
DR   Antibodypedia; 1749; 1064 antibodies from 41 providers.
DR   CPTC; Q12888; 1 antibody.
DR   DNASU; 7158; -.
DR   Ensembl; ENST00000263801.7; ENSP00000263801.3; ENSG00000067369.14. [Q12888-1]
DR   Ensembl; ENST00000382044.9; ENSP00000371475.5; ENSG00000067369.14. [Q12888-2]
DR   Ensembl; ENST00000450115.6; ENSP00000393497.2; ENSG00000067369.14. [Q12888-3]
DR   GeneID; 7158; -.
DR   KEGG; hsa:7158; -.
DR   MANE-Select; ENST00000382044.9; ENSP00000371475.5; NM_001141980.3; NP_001135452.1. [Q12888-2]
DR   UCSC; uc001zrq.5; human. [Q12888-1]
DR   AGR; HGNC:11999; -.
DR   CTD; 7158; -.
DR   DisGeNET; 7158; -.
DR   GeneCards; TP53BP1; -.
DR   HGNC; HGNC:11999; TP53BP1.
DR   HPA; ENSG00000067369; Low tissue specificity.
DR   MalaCards; TP53BP1; -.
DR   MIM; 605230; gene.
DR   neXtProt; NX_Q12888; -.
DR   OpenTargets; ENSG00000067369; -.
DR   PharmGKB; PA36680; -.
DR   VEuPathDB; HostDB:ENSG00000067369; -.
DR   eggNOG; KOG3548; Eukaryota.
DR   GeneTree; ENSGT00390000011891; -.
DR   HOGENOM; CLU_002167_0_0_1; -.
DR   InParanoid; Q12888; -.
DR   OMA; EPCVENR; -.
DR   OrthoDB; 5403076at2759; -.
DR   PhylomeDB; Q12888; -.
DR   TreeFam; TF350227; -.
DR   PathwayCommons; Q12888; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q12888; -.
DR   SIGNOR; Q12888; -.
DR   BioGRID-ORCS; 7158; 38 hits in 1177 CRISPR screens.
DR   ChiTaRS; TP53BP1; human.
DR   EvolutionaryTrace; Q12888; -.
DR   GeneWiki; TP53BP1; -.
DR   GenomeRNAi; 7158; -.
DR   Pharos; Q12888; Tbio.
DR   PRO; PR:Q12888; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q12888; protein.
DR   Bgee; ENSG00000067369; Expressed in pituitary gland and 198 other tissues.
DR   ExpressionAtlas; Q12888; baseline and differential.
DR   Genevisible; Q12888; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ProtInc.
DR   GO; GO:1990391; C:DNA repair complex; IEA:Ensembl.
DR   GO; GO:0000776; C:kinetochore; IEA:UniProtKB-KW.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0042393; F:histone binding; IBA:GO_Central.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:AgBase.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IEA:Ensembl.
DR   GO; GO:0003712; F:transcription coregulator activity; IMP:BHF-UCL.
DR   GO; GO:0061649; F:ubiquitin modification-dependent histone binding; IDA:UniProtKB.
DR   GO; GO:0071481; P:cellular response to X-ray; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IDA:UniProtKB.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IC:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0045830; P:positive regulation of isotype switching; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   CDD; cd17745; BRCT_p53bp1_rpt1; 1.
DR   CDD; cd17724; BRCT_p53bp1_rpt2; 1.
DR   CDD; cd20383; Tudor_53BP1; 1.
DR   DisProt; DP02954; -.
DR   Gene3D; 2.30.30.140; -; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 3.40.50.10190; BRCT domain; 2.
DR   IDEAL; IID00123; -.
DR   InterPro; IPR015125; 53-BP1_Tudor.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR047249; BRCT_p53bp1-like_rpt1.
DR   InterPro; IPR047250; BRCT_p53bp1-like_rpt2.
DR   InterPro; IPR014722; Rib_L2_dom2.
DR   InterPro; IPR047252; TP53BP1-like.
DR   PANTHER; PTHR15321:SF3; TP53-BINDING PROTEIN 1; 1.
DR   PANTHER; PTHR15321; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1; 1.
DR   Pfam; PF09038; 53-BP1_Tudor; 1.
DR   Pfam; PF18428; BRCT_3; 1.
DR   SMART; SM00292; BRCT; 2.
DR   SUPFAM; SSF52113; BRCT domain; 2.
DR   SUPFAM; SSF63748; Tudor/PWWP/MBT; 2.
DR   PROSITE; PS50172; BRCT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Centromere;
KW   Chromosomal rearrangement; Chromosome; DNA damage; DNA repair; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Kinetochore; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1972
FT                   /note="TP53-binding protein 1"
FT                   /id="PRO_0000072643"
FT   DOMAIN          1724..1848
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1864..1964
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   REGION          24..273
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          290..332
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          346..507
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          520..556
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          568..595
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          649..687
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          742..911
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          997..1028
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1045..1103
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1127..1148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1188..1232
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1269..1478
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1484..1603
FT                   /note="Tudor-like"
FT                   /evidence="ECO:0000305|PubMed:17190600"
FT   REGION          1495..1523
FT                   /note="Interaction with dimethylated histone H4"
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   REGION          1622..1719
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1745..1768
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1396..1403
FT                   /note="GAR"
FT                   /evidence="ECO:0000269|PubMed:16294045"
FT   MOTIF           1604..1631
FT                   /note="UDR"
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   COMPBIAS        31..63
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        76..92
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        93..124
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        130..152
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        153..209
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        346..366
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        424..441
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        452..469
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        580..595
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        794..822
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        848..878
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        887..905
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1068..1082
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1188..1202
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1216..1232
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1284..1329
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1632..1655
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1669..1683
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19176521"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         166
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         176
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:17553757"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:17553757"
FT   MOD_RES         222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         265
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         302
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332"
FT   MOD_RES         366
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         464
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         500
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         543
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         548
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         552
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         566
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         630
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         635
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         639
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         640
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         724
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         727
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         809
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         830
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648"
FT   MOD_RES         834
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         855
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         922
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         970
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         975
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1028
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1056
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1068
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1086
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         1094
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1214
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         1216
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1219
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1355
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         1362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1372
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1426
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1430
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1460
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1462
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1609
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:24703952,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1618
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:24703952,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1631
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         1635
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1638
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1648
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1656
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1673
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1678
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1701
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1778
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19176521,
FT                   ECO:0000269|PubMed:21144835"
FT   CROSSLNK        217
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        217
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        868
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        868
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        930
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        984
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1365
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        1434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1563
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        1563
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1
FT                   /note="M -> MPGEQM (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005, ECO:0000303|Ref.2"
FT                   /id="VSP_018390"
FT   VAR_SEQ         1692..1693
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_055062"
FT   VARIANT         353
FT                   /note="D -> E (in dbSNP:rs560191)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022172"
FT   VARIANT         412
FT                   /note="G -> S (in dbSNP:rs689647)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022173"
FT   VARIANT         648
FT                   /note="M -> V (in dbSNP:rs45443496)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022174"
FT   VARIANT         699
FT                   /note="Q -> R (in dbSNP:rs34823068)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022175"
FT   VARIANT         841
FT                   /note="D -> G (in dbSNP:rs34185035)"
FT                   /id="VAR_034558"
FT   VARIANT         1014
FT                   /note="E -> G (in dbSNP:rs45470395)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022176"
FT   VARIANT         1026
FT                   /note="V -> A (in dbSNP:rs45482998)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022177"
FT   VARIANT         1136
FT                   /note="K -> Q (in dbSNP:rs2602141)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022178"
FT   VARIANT         1137
FT                   /note="E -> K (in dbSNP:rs34740611)"
FT                   /id="VAR_034559"
FT   VARIANT         1170
FT                   /note="A -> G (in dbSNP:rs45500399)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022179"
FT   VARIANT         1174
FT                   /note="I -> V (in dbSNP:rs3803339)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022180"
FT   VARIANT         1442
FT                   /note="R -> Q (in dbSNP:rs2230449)"
FT                   /id="VAR_034560"
FT   VARIANT         1488
FT                   /note="G -> W (in dbSNP:rs11554564)"
FT                   /id="VAR_038689"
FT   MUTAGEN         6
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-13; A-25; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         13
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-25; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         25
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         29
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         105
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-166; A-176; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         166
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-176; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         176..178
FT                   /note="SQS->AQA: Loss of phosphorylation site."
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MUTAGEN         176
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-166
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         178
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-166
FT                   and A-176."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         302
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         437
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         452
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         523
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         543
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         580
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         625
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         674
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         696
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         698
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         784
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         831
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         855
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         892
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1068
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1086
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1104
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1148
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1171
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1219
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148
FT                   and A-1171."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1396
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1398; A-1400; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1396
FT                   /note="R->K: No detectable effect on methylation by PRMT1
FT                   (in vitro)."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1398..1401
FT                   /note="RGRR->AGAA: No effect on in class-switch
FT                   recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1398
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1400; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1398
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1400.
FT                   Strongly reduced methylation; when associated with K-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1400
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1400
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1398.
FT                   Strongly reduced methylation; when associated with K-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1401
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1400 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1401
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1398.
FT                   Strongly reduced methylation; when associated with K-1400."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1403
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1400 and A-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1403
FT                   /note="R->K: No detectable effect on methylation by PRMT1
FT                   (in vitro)."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1495
FT                   /note="W->A,H: Loss of interaction with histone H4 that has
FT                   been dimethylated at 'Lys-20' (H4K20me2). Abolishes
FT                   recruitment to double strand breaks. Loss of interaction
FT                   with histone H4 that has been dimethylated at 'Lys-20'
FT                   (H4K20me2). Abolishes recruitment to double strand breaks;
FT                   when associated with A-1521."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:28241136"
FT   MUTAGEN         1495
FT                   /note="W->F: No effect on recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1495
FT                   /note="W->V: Reduces recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1500
FT                   /note="Y->A: Reduces affinity for histone H4 that has been
FT                   dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1502
FT                   /note="Y->A: Reduces affinity for histone H4 that has been
FT                   dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1502
FT                   /note="Y->L,Q: Abolishes recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1521
FT                   /note="D->A: Loss of interaction with histone H4 that has
FT                   been dimethylated at 'Lys-20' (H4K20me2). Abolishes
FT                   recruitment to double strand breaks. Loss of interaction
FT                   with histone H4 that has been dimethylated at 'Lys-20'
FT                   (H4K20me2). Abolishes recruitment to double strand breaks;
FT                   when associated with A-1495."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:28241136"
FT   MUTAGEN         1521
FT                   /note="D->R: Abolishes recruitment to double strand breaks
FT                   and induces defects in class-switch recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:23345425,
FT                   ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1523
FT                   /note="Y->A: Increases affinity for histone H4 that has
FT                   been dimethylated at 'Lys-20'. No effect on recruitment to
FT                   double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1523
FT                   /note="Y->S: Decreases affinity for histone H4 that has
FT                   been dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1609
FT                   /note="T->A: Constitutive recruitment to mitotic DNA
FT                   lesions, leading to mitotic defects; when associated with
FT                   A-1618."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1609
FT                   /note="T->E: Phosphomimetic mutant that abolishes
FT                   recruitment to double strand breaks; when associated with
FT                   D-1618."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1613
FT                   /note="K->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1616
FT                   /note="D->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1617
FT                   /note="I->A: Strongly reduced recruitment to double strand
FT                   breaks. Defects in class-switch recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1618
FT                   /note="S->A: Constitutive recruitment to mitotic DNA
FT                   lesions, leading to mitotic defects; when associated with
FT                   A-1609."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1618
FT                   /note="S->D: Phosphomimetic mutant that abolishes
FT                   recruitment to double strand breaks; when associated with
FT                   E-1609."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1619
FT                   /note="L->A: Strongly reduced recruitment to double strand
FT                   breaks. Defects in class-switch recombination (CSR). Does
FT                   not affect interaction with histone H4 dimethylated at
FT                   'Lys-20' (H4K20me2). Impaired interaction with histone H2A
FT                   monoubiquitinated at 'Lys-15' (H2AK15ub)."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1621
FT                   /note="N->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1622
FT                   /note="L->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1624
FT                   /note="E->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1627
FT                   /note="R->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   CONFLICT        796
FT                   /note="P -> S (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1600
FT                   /note="Y -> C (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1958
FT                   /note="G -> R (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1490..1494
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   TURN            1496..1498
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1501..1511
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1514..1519
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1524..1528
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1529..1531
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1532..1535
FT                   /evidence="ECO:0007829|PDB:2LVM"
FT   STRAND          1543..1547
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   TURN            1549..1551
FT                   /evidence="ECO:0007829|PDB:6VA5"
FT   STRAND          1553..1564
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1567..1574
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1577..1582
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1583..1585
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1586..1588
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1590..1594
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1597..1600
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   TURN            1674..1676
FT                   /evidence="ECO:0007829|PDB:6IUA"
FT   HELIX           1715..1719
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1726..1731
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1732..1736
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1741..1745
FT                   /evidence="ECO:0007829|PDB:1GZH"
FT   HELIX           1773..1781
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1782..1784
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1793..1799
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1801..1808
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1813..1821
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1825..1827
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1829..1837
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1843..1845
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1851..1853
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1854..1857
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1858..1860
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1868..1871
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1873..1879
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1881..1884
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1885..1894
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1898..1908
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1914..1916
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1918..1922
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1928..1937
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1944..1953
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1963..1965
FT                   /evidence="ECO:0007829|PDB:1KZY"
SQ   SEQUENCE   1972 AA;  213574 MW;  13E2CC8A265F9D2A CRC64;
     MDPTGSQLDS DFSQQDTPCL IIEDSQPESQ VLEDDSGSHF SMLSRHLPNL QTHKENPVLD
     VVSNPEQTAG EERGDGNSGF NEHLKENKVA DPVDSSNLDT CGSISQVIEQ LPQPNRTSSV
     LGMSVESAPA VEEEKGEELE QKEKEKEEDT SGNTTHSLGA EDTASSQLGF GVLELSQSQD
     VEENTVPYEV DKEQLQSVTT NSGYTRLSDV DANTAIKHEE QSNEDIPIAE QSSKDIPVTA
     QPSKDVHVVK EQNPPPARSE DMPFSPKASV AAMEAKEQLS AQELMESGLQ IQKSPEPEVL
     STQEDLFDQS NKTVSSDGCS TPSREEGGCS LASTPATTLH LLQLSGQRSL VQDSLSTNSS
     DLVAPSPDAF RSTPFIVPSS PTEQEGRQDK PMDTSVLSEE GGEPFQKKLQ SGEPVELENP
     PLLPESTVSP QASTPISQST PVFPPGSLPI PSQPQFSHDI FIPSPSLEEQ SNDGKKDGDM
     HSSSLTVECS KTSEIEPKNS PEDLGLSLTG DSCKLMLSTS EYSQSPKMES LSSHRIDEDG
     ENTQIEDTEP MSPVLNSKFV PAENDSILMN PAQDGEVQLS QNDDKTKGDD TDTRDDISIL
     ATGCKGREET VAEDVCIDLT CDSGSQAVPS PATRSEALSS VLDQEEAMEI KEHHPEEGSS
     GSEVEEIPET PCESQGEELK EENMESVPLH LSLTETQSQG LCLQKEMPKK ECSEAMEVET
     SVISIDSPQK LAILDQELEH KEQEAWEEAT SEDSSVVIVD VKEPSPRVDV SCEPLEGVEK
     CSDSQSWEDI APEIEPCAEN RLDTKEEKSV EYEGDLKSGT AETEPVEQDS SQPSLPLVRA
     DDPLRLDQEL QQPQTQEKTS NSLTEDSKMA NAKQLSSDAE AQKLGKPSAH ASQSFCESSS
     ETPFHFTLPK EGDIIPPLTG ATPPLIGHLK LEPKRHSTPI GISNYPESTI ATSDVMSESM
     VETHDPILGS GKGDSGAAPD VDDKLCLRMK LVSPETEASE ESLQFNLEKP ATGERKNGST
     AVAESVASPQ KTMSVLSCIC EARQENEARS EDPPTTPIRG NLLHFPSSQG EEEKEKLEGD
     HTIRQSQQPM KPISPVKDPV SPASQKMVIQ GPSSPQGEAM VTDVLEDQKE GRSTNKENPS
     KALIERPSQN NIGIQTMECS LRVPETVSAA TQTIKNVCEQ GTSTVDQNFG KQDATVQTER
     GSGEKPVSAP GDDTESLHSQ GEEEFDMPQP PHGHVLHRHM RTIREVRTLV TRVITDVYYV
     DGTEVERKVT EETEEPIVEC QECETEVSPS QTGGSSGDLG DISSFSSKAS SLHRTSSGTS
     LSAMHSSGSS GKGAGPLRGK TSGTEPADFA LPSSRGGPGK LSPRKGVSQT GTPVCEEDGD
     AGLGIRQGGK APVTPRGRGR RGRPPSRTTG TRETAVPGPL GIEDISPNLS PDDKSFSRVV
     PRVPDSTRRT DVGAGALRRS DSPEIPFQAA AGPSDGLDAS SPGNSFVGLR VVAKWSSNGY
     FYSGKITRDV GAGKYKLLFD DGYECDVLGK DILLCDPIPL DTEVTALSED EYFSAGVVKG
     HRKESGELYY SIEKEGQRKW YKRMAVILSL EQGNRLREQY GLGPYEAVTP LTKAADISLD
     NLVEGKRKRR SNVSSPATPT ASSSSSTTPT RKITESPRAS MGVLSGKRKL ITSEEERSPA
     KRGRKSATVK PGAVGAGEFV SPCESGDNTG EPSALEEQRG PLPLNKTLFL GYAFLLTMAT
     TSDKLASRSK LPDGPTGSSE EEEEFLEIPP FNKQYTESQL RAGAGYILED FNEAQCNTAY
     QCLLIADQHC RTRKYFLCLA SGIPCVSHVW VHDSCHANQL QNYRNYLLPA GYSLEEQRIL
     DWQPRENPFQ NLKVLLVSDQ QQNFLELWSE ILMTGGAASV KQHHSSAHNK DIALGVFDVV
     VTDPSCPASV LKCAEALQLP VVSQEWVIQC LIVGERIGFK QHPKYKHDYV SH
//
